Every CFO's nightmare: your company just spent millions on AI pilots, and nobody can tell you what you got for it. Healthcare enterprises will pour $18 billion into AI this year, but IBM's February 2026 enterprise AI report dropped a bombshell—only 5% achieve what they call "substantial ROI." That means 95% of organizations can't confidently measure whether their AI investments improved the bottom line beyond implementation costs.

Enter Optura, which just raised $17.5 million in Series A funding led by Salesforce Ventures to solve what might be enterprise AI's most expensive blind spot. The company isn't selling yet another AI model—it's selling something CFOs desperately need: proof that AI spending isn't just lighting money on fire.

The $18 Billion Black Hole

Here's the uncomfortable truth most vendors don't want to discuss: AI has a measurement problem. Companies are running dozens of generative AI pilots, executives are demanding results, and IT teams are scrambling to quantify value using metrics that don't connect to P&L statements.

"We saved employees 2 hours per week" sounds impressive until your CFO asks what that translates to in margin improvement or revenue growth. That's the gap Optura identified in healthcare, where AI spending is exploding but financial accountability remains elusive.

The company's platform manages over $2 billion in AI initiatives for major clients including Independence Blue Cross, Prime Therapeutics, and Ardent Health. More importantly, it's tracking $120 million in documented value with a 700% Return on AI Investment (ROAI™) for ongoing initiatives. Those aren't vanity metrics—they're the kind of numbers that survive board scrutiny.

Why Traditional ROI Frameworks Break Down

The old playbook assumed AI projects behaved like traditional IT implementations. You'd calculate total cost of ownership, estimate efficiency gains, multiply by headcount savings, and present a three-year payback model. That framework collapses when you're dealing with generative AI that touches multiple workflows, generates probabilistic outputs, and requires continuous model updates.

Optura's approach recognizes this reality. Their proprietary ROAI™ methodology doesn't start with technology—it starts with business priorities:

Step 1: Map fragmented data into a unified knowledge layer. Most enterprises have data scattered across EHRs, claims systems, clinical workflows, and administrative tools. AI can't deliver ROI if it's working with incomplete or siloed information.

Step 2: Score and prioritize use cases based on organizational readiness. Not every AI opportunity deserves funding. Optura evaluates cost, technical feasibility, and strategic alignment before any pilot launches.

Step 3: Build specialized AI agents directly from existing workflows. This isn't about replacing entire departments—it's about augmenting specific processes where AI can deliver measurable lift.

Step 4: Simulate financial returns before deployment. Here's where Optura separates itself from typical AI vendors. Before a single dollar gets spent on production infrastructure, the platform models expected P&L impact. CFOs get projections they can validate against actuals.

Step 5: Monitor real-time impact via centralized dashboard. Once deployed, Optura tracks outcomes, initiatives, and projected value continuously. When something underperforms, leadership knows immediately—not six months into a failing pilot.

What Salesforce Sees That Others Missed

Salesforce Ventures doesn't write $17.5 million checks on hype. Their thesis is straightforward: as agentic AI moves from experimental to production, enterprises need infrastructure that connects AI outputs to financial statements. Optura's platform fills that gap.

The funding round (which brought total capital raised to over $25 million, with participation from Echo Health Ventures and continued investment from Susa Ventures, Matrix Partners, and HC9 Ventures) will accelerate platform development, expand partnerships with large language model providers, and scale customer success teams.

But the strategic signal matters more than the dollar amount. Salesforce is betting that AI ROI measurement becomes a standalone category—not a feature bolted onto existing observability tools or BI platforms. That's a significant shift from 2025, when most CIOs assumed their existing analytics stack could handle AI measurement.

The Shift from Soft ROI to Hard ROI

Here's what changed in 2026: companies stopped accepting "improved employee satisfaction" or "faster time to insights" as success metrics. Boards and CFOs now demand direct impact on revenue, sales conversion rates, and labor cost per worker.

This isn't about productivity theater—it's about P&L accountability. Among the 56% of companies seeing positive AI ROI (per recent industry surveys), more than half report measurable improvements in overall financial performance. The other half? They're still stuck measuring activity instead of outcomes.

Optura's clients represent the former category. When Independence Blue Cross or Prime Therapeutics reports AI value, they're not citing developer velocity or survey sentiment—they're showing margin expansion, cost reduction, and revenue uplift tied to specific AI agents.

What This Means for Enterprise AI Leaders

For CFOs: You finally have a framework to evaluate AI spending using the same rigor you apply to capital expenditures or M&A. If your CIO can't articulate expected ROAI before launching a pilot, you're funding science experiments, not strategic initiatives.

For CIOs and CTOs: The bar just got higher. "We're experimenting with AI" no longer justifies budget allocation. You need pre-deployment financial modeling, continuous performance tracking, and the ability to kill underperforming projects before they become sunk costs.

For COOs and business unit leaders: AI vendors will promise efficiency gains and automation. Demand proof. Optura's 700% ROAI benchmark isn't universal, but it demonstrates what's possible when AI projects are designed with measurement from day one.

For CHROs and talent leaders: Only 17% of companies seeing AI ROI use productivity gains for headcount reduction. The majority reinvest in AI capabilities, cybersecurity, R&D, and strategic growth. If your leadership team assumes AI automatically means layoffs, you're solving the wrong problem.

The Healthcare Wedge Strategy

Optura started in healthcare for good reason: it's a regulated, data-rich environment where ROI measurement directly impacts compliance and reimbursement. If you can prove AI reduces claims processing costs or improves patient outcomes, you've solved a billion-dollar problem.

But the methodology isn't healthcare-specific. Any industry with complex workflows, fragmented data, and high AI spending can use Optura's framework. Financial services, manufacturing, retail, and professional services all face the same challenge—how do you know if your AI investments are working?

The company's $2 billion in managed initiatives suggests they're not positioning as a niche healthcare tool. This is infrastructure for the agentic AI era, where autonomous agents handle workflows and executives need real-time visibility into what's working and what's burning cash.

What Comes Next

Optura's Series A marks an inflection point: AI ROI measurement is now a fundable category backed by tier-one investors. Expect competitors to emerge, existing observability vendors to add ROAI modules, and hyperscalers to integrate measurement frameworks into their AI platforms.

But first-mover advantage matters here. Optura has production deployments with major enterprises, validated methodology for financial modeling, and real-world benchmarks (like that 700% ROAI figure) that competitors will struggle to match without years of customer data.

For enterprise leaders, the lesson is clear: if you're spending millions on AI without pre-deployment financial modeling and continuous ROI tracking, you're flying blind. The 5% who measure returns aren't smarter—they just use better tools.

Optura's $17.5 million raise won't fix the industry's $18 billion measurement problem overnight. But it's the first serious attempt to build infrastructure that treats AI ROI as a first-class metric, not an afterthought.

The question isn't whether your company will adopt AI—it's whether you'll know if it was worth it.